Marathon Pharmaceuticals Names Greg Aronin Vice President of Government Affairs

WASHINGTON--(BUSINESS WIRE)--Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare diseases, today announced that Greg Aronin has joined the company as vice president of government affairs. Mr. Aronin (43) will manage Marathon's Washington, D.C. office and oversee all of Marathon's government affairs and policy matters as well as new business activities in the D.C. area.

Mr. Aronin's experience in government affairs spans more than two decades. Prior to joining Marathon's executive team, Mr. Aronin spent 11 years leading government affairs efforts for multiple Johnson & Johnson companies, supporting a $10 billion annual portfolio of drug, device and diagnostic therapeutic areas.

During his tenure at Johnson & Johnson, Mr. Aronin led the company's engagement with members of Congress and key committee staff to reform the Medicare payment system for diagnostics, which ultimately played a critical role in stabilizing the U.S. diagnostic industry. In addition to bringing a renewed focus and appreciation for constituent education and engagement to drive the political process, Mr. Aronin established Johnson & Johnson's first-in-class beltway reputation initiative.

Prior to joining Johnson & Johnson, Greg led regional government and managed care efforts for MedPointe pharmaceuticals and began his career directing government affairs activities for the 17,000 physician member medical society in Michigan.

Aronin earned his Master of Public Health at the University of Michigan and a bachelor degree in International Relations at James Madison College of Michigan State University.

Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.

Contacts

Aileron Communications
Peter Gray, 312.629.9400
[email protected]

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.